<DOC>
	<DOCNO>NCT01230801</DOCNO>
	<brief_summary>A Phase 1/2 , open-label , multicenter , multiple dose escalation study BMN 701 administer intravenous infusion every 2 week 24-week treatment period patient late-onset Pompe disease .</brief_summary>
	<brief_title>Safety/Tolerability/Pharmacokinetic ( PK ) /Pharmacodynamics ( PD ) Study BMN701 Patients With Late-Onset Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<criteria>Inclusion criterion : Patient patient 's parent legal guardian provide write informed consent nature study explain , prior studyrelated procedure ; Patient diagnose Pompe Disease prior screen period base 2 GAA gene mutation either : endogenous GAA activity &lt; 75 % low limit normal adult range report test laboratory , assess cultured skin fibroblast endogenous GAA activity &lt; 75 % low limit normal adult range report test laboratory , assess dry blood spot whole blood assay ; Patient male female 13 year age old time enrollment study ; Sexually active patient must willing use acceptable method contraception participate study least 30 day follow last dose BMN 701 ; If patient female consider childbearing potential , least 2 year postmenopausal tubal ligation least 1 year prior screening , total hysterectomy ; If patient female childbearing potential , negative urine pregnancy test Screening Period Baseline visit willing additional pregnancy test study ; Patient ≥30 % predict upright FVC either &lt; 80 % predict upright FVC , &gt; 10 % reduction supine FVC compare upright FVC Screening Period ; Patient naïve Enzyme Replacement Therapy ( ERT ) rhGAA ; Patient must able ambulate least 40 meter ( 131.2 foot ) 6MWT conduct Screening visit ( use assistive device walker , cane , crutch , permit ) ; Patient ability comply protocol requirement , opinion Investigator . Exclusion criterion : Patient history diabetes disease know cause hypoglycemia currently receive , might anticipate receiving , hypoglycemic agent course study ; Patient immunosuppressive medication glucocorticosteroids within 1 year prior enrollment study ; Patient require invasive ventilatory assistance time enrollment study ; Patient receive investigational medication within 30 day prior first dose study drug schedule receive investigational drug BMN 701 course study ; Patient previously admit study ; Patient breastfeed screen plan become pregnant ( self partner ) time study ; Patient medical condition extenuate circumstance , opinion Investigator , might compromise patient 's ability comply protocol requirement compromise patient 's well safety ; Patient condition , view Investigator , place patient high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>